Abstract
Recent publications reveal the mechanism of action of apolipoprotein A-I (apoA-I) mimetic peptides to be the remarkable binding affinity that oxidized lipids have for these peptides compared with apoA-I. There was no difference in the binding affinity of oxidized lipids or in peptide efficacy in reducing inflammation and atherosclerosis in rabbits injected with peptides synthesized from all D- or all L-amino acids. The apoA-I mimetic peptide 4F increased the formation of pre-beta high-density lipoprotein, increased cholesterol efflux, and reduced lipoprotein oxidation in vitro; it increased antioxidants and vascular repair in type 1 diabetic rats; it improved vasodilation, oxidative stress, myocardial inflammation, and angiogenic potential in a mouse model of scleroderma; it reduced renal inflammation in low-density lipoprotein receptor-null mice fed a Western diet; it reduced arthritis in a rat model; it reduced adiposity, increased adiponectin levels, and improved insulin sensitivity in obese mice; and it improved high-density lipoprotein inflammatory properties in humans with coronary heart disease.
MeSH Terms
Animals
Anti-Inflammatory Agents/pharmacology,therapeutic use
Apolipoprotein A-I/pharmacology,therapeutic use
Arthritis/drug therapy
Atherosclerosis/prevention & control
Cholesterol, HDL/blood
Diabetes Mellitus/drug therapy
Disease Models, Animal
Humans
Hyperlipidemias/complications
Nephritis/drug therapy,etiology
Obesity/drug therapy
Scleroderma, Systemic/drug therapy
Chemicals
Anti-Inflammatory Agents
Apolipoprotein A-I
Cholesterol, HDL
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Van Lenten Brian J
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
[email protected]
Wagner Alan C
Anantharamaiah G M
Navab Mohamad
Reddy Srinivasa T
Buga Georgette M
Fogelman Alan M
References (16)
16 references, click to expand
-
D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet.
J Lipid Res. 2008 Jan;49(1):192-205
PMID: 17925450
-
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Circulation. 2004 Jun 29;109(25):3215-20
PMID: 15197147
-
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.
J Am Coll Cardiol. 2008 Jun 10;51(23):2199-211
PMID: 18534265
-
Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats.
J Pharmacol Exp Ther. 2007 Aug;322(2):514-20
PMID: 17488882
-
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.
J Lipid Res. 2000 Sep;41(9):1495-508
PMID: 10974057
-
Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice.
Am J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1432-41
PMID: 17496220
-
L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice.
J Lipid Res. 2008 Aug;49(8):1658-69
PMID: 18426778
-
Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits.
J Lipid Res. 2007 Nov;48(11):2344-53
PMID: 17693626
-
Treatment with an apolipoprotein A-1 mimetic peptide in combination with pravastatin inhibits collagen-induced arthritis.
Clin Immunol. 2008 May;127(2):234-44
PMID: 18337176
-
Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.
J Lipid Res. 2001 Jul;42(7):1096-104
PMID: 11441137
-
Apolipoprotein A-I mimetic peptides.
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1325-31
PMID: 15831812
-
Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides.
J Lipid Res. 2007 Sep;48(9):1915-23
PMID: 17570869
-
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients.
J Lipid Res. 2008 Jun;49(6):1344-52
PMID: 18323573
-
An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma.
J Lipid Res. 2008 Mar;49(3):581-7
PMID: 18056684
-
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I.
J Lipid Res. 2008 Nov;49(11):2302-11
PMID: 18621920
-
Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
J Lipid Res. 2008 Jun;49(6):1268-83
PMID: 18323574